Ansan, South Korea

Hoejin Yoon

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: St Pharm Co., Ltd.. Active years: 2024.


% Patents Active = 100.0


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hoejin Yoon: Innovator in Pharmaceutical Chemistry

Introduction

Hoejin Yoon is a prominent inventor based in Ansan, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the preparation of gadobutrol, a contrast agent used in medical imaging. His innovative approach has the potential to streamline production processes and enhance the quality of pharmaceutical products.

Latest Patents

Hoejin Yoon holds a patent for a novel method for preparing high-purity gadobutrol. This method simplifies the process by forming a gadolinium complex in-situ, eliminating the need for purification of a butrol intermediate and a resin purification process. The advantages of this preparation method include high yield and the ability to produce gadobutrol or its hydrates efficiently, making it beneficial for mass production.

Career Highlights

Yoon is associated with St Pharm Co., Ltd., where he applies his expertise in pharmaceutical development. His work focuses on improving the synthesis of gadobutrol, contributing to advancements in medical imaging technology. With 1 patent to his name, he continues to push the boundaries of innovation in his field.

Collaborations

Some of Hoejin Yoon's notable coworkers include Sun Ki Chang and Moonsu Kim. Their collaborative efforts contribute to the ongoing research and development initiatives at St Pharm Co., Ltd.

Conclusion

Hoejin Yoon's innovative methods in the preparation of gadobutrol exemplify the impact of inventive thinking in pharmaceutical chemistry. His contributions are paving the way for more efficient production processes in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…